vs
Apellis Pharmaceuticals, Inc.（APLS）与Childrens Place, Inc.（PLCE）财务数据对比。点击上方公司名可切换其他公司
Childrens Place, Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.7倍（$339.5M vs $199.9M），Childrens Place, Inc.净利率更高（-1.3% vs -29.5%，领先28.2%），Apellis Pharmaceuticals, Inc.同比增速更快（-5.9% vs -13.0%），Childrens Place, Inc.自由现金流更多（$-3.4M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -13.6%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Children’s Place是专业儿童服饰零售商，产品主要以旗下自有品牌发售，涵盖Gymboree、Sugar & Jade、PJ Place、Crazy 8等。目前该品牌在美国、加拿大、波多黎各共开设约525家门店，同时通过两个线上渠道以及15个国家的5家加盟合作伙伴开展销售，产品涵盖上衣、裙装、鞋履、裤装、睡衣、背包等全品类儿童服饰配件。
APLS vs PLCE — 直观对比
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $339.5M |
| 净利润 | $-59.0M | $-4.3M |
| 毛利率 | — | 33.1% |
| 营业利润率 | -25.6% | 1.1% |
| 净利率 | -29.5% | -1.3% |
| 营收同比 | -5.9% | -13.0% |
| 净利润同比 | -62.2% | -121.5% |
| 每股收益（稀释后） | $-0.40 | $-0.19 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $339.5M | ||
| Q3 25 | $458.6M | $298.0M | ||
| Q2 25 | $178.5M | $242.1M | ||
| Q1 25 | $166.8M | $408.6M | ||
| Q4 24 | $212.5M | $390.2M | ||
| Q3 24 | $196.8M | $319.7M | ||
| Q2 24 | $199.7M | $267.9M | ||
| Q1 24 | $172.3M | $455.0M |
| Q4 25 | $-59.0M | $-4.3M | ||
| Q3 25 | $215.7M | $-5.4M | ||
| Q2 25 | $-42.2M | $-34.0M | ||
| Q1 25 | $-92.2M | $-8.0M | ||
| Q4 24 | $-36.4M | $20.1M | ||
| Q3 24 | $-57.4M | $-32.1M | ||
| Q2 24 | $-37.7M | $-37.8M | ||
| Q1 24 | $-66.4M | $-128.8M |
| Q4 25 | — | 33.1% | ||
| Q3 25 | — | 34.0% | ||
| Q2 25 | — | 29.2% | ||
| Q1 25 | — | 28.5% | ||
| Q4 24 | — | 35.5% | ||
| Q3 24 | — | 35.0% | ||
| Q2 24 | — | 34.6% | ||
| Q1 24 | — | 21.8% |
| Q4 25 | -25.6% | 1.1% | ||
| Q3 25 | 48.7% | 1.4% | ||
| Q2 25 | -18.6% | -10.0% | ||
| Q1 25 | -50.0% | 1.7% | ||
| Q4 24 | -12.3% | 7.5% | ||
| Q3 24 | -24.0% | -6.8% | ||
| Q2 24 | -14.7% | -10.4% | ||
| Q1 24 | -36.0% | -13.6% |
| Q4 25 | -29.5% | -1.3% | ||
| Q3 25 | 47.0% | -1.8% | ||
| Q2 25 | -23.6% | -14.1% | ||
| Q1 25 | -55.3% | -2.0% | ||
| Q4 24 | -17.1% | 5.1% | ||
| Q3 24 | -29.2% | -10.0% | ||
| Q2 24 | -18.9% | -14.1% | ||
| Q1 24 | -38.5% | -28.3% |
| Q4 25 | $-0.40 | $-0.19 | ||
| Q3 25 | $1.67 | $-0.24 | ||
| Q2 25 | $-0.33 | $-1.57 | ||
| Q1 25 | $-0.74 | $-0.60 | ||
| Q4 24 | $-0.30 | $1.57 | ||
| Q3 24 | $-0.46 | $-2.51 | ||
| Q2 24 | $-0.30 | $-2.98 | ||
| Q1 24 | $-0.54 | $-10.24 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $7.3M |
| 总债务越低越好 | — | $107.4M |
| 股东权益账面价值 | $370.1M | $-8.6M |
| 总资产 | $1.1B | $762.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $7.3M | ||
| Q3 25 | $479.2M | $7.8M | ||
| Q2 25 | $370.0M | $5.7M | ||
| Q1 25 | $358.4M | $5.3M | ||
| Q4 24 | $411.3M | $5.7M | ||
| Q3 24 | $396.9M | $9.6M | ||
| Q2 24 | $360.1M | $13.0M | ||
| Q1 24 | $325.9M | $13.6M |
| Q4 25 | — | $107.4M | ||
| Q3 25 | — | $107.2M | ||
| Q2 25 | — | $107.0M | ||
| Q1 25 | — | $166.0M | ||
| Q4 24 | — | $165.7M | ||
| Q3 24 | — | $165.4M | ||
| Q2 24 | — | $166.6M | ||
| Q1 24 | $93.1M | $49.8M |
| Q4 25 | $370.1M | $-8.6M | ||
| Q3 25 | $401.2M | $-4.9M | ||
| Q2 25 | $156.3M | $1.4M | ||
| Q1 25 | $164.2M | $-59.4M | ||
| Q4 24 | $228.5M | $-49.6M | ||
| Q3 24 | $237.1M | $-68.9M | ||
| Q2 24 | $264.3M | $-34.9M | ||
| Q1 24 | $266.7M | $-9.0M |
| Q4 25 | $1.1B | $762.5M | ||
| Q3 25 | $1.1B | $805.1M | ||
| Q2 25 | $821.4M | $779.6M | ||
| Q1 25 | $807.3M | $747.6M | ||
| Q4 24 | $885.1M | $888.8M | ||
| Q3 24 | $901.9M | $921.4M | ||
| Q2 24 | $904.5M | $848.3M | ||
| Q1 24 | $831.9M | $800.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 75.63× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $6.2M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-3.4M |
| 自由现金流率自由现金流/营收 | -7.1% | -1.0% |
| 资本支出强度资本支出/营收 | 0.1% | 2.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $39.5M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $6.2M | ||
| Q3 25 | $108.5M | $-30.5M | ||
| Q2 25 | $4.4M | $-43.0M | ||
| Q1 25 | $-53.4M | $121.3M | ||
| Q4 24 | $19.4M | $-44.2M | ||
| Q3 24 | $34.1M | $-83.9M | ||
| Q2 24 | $-8.3M | $-110.8M | ||
| Q1 24 | $-133.0M | $135.4M |
| Q4 25 | $-14.3M | $-3.4M | ||
| Q3 25 | $108.3M | $-31.9M | ||
| Q2 25 | $4.4M | $-46.4M | ||
| Q1 25 | $-53.4M | $121.2M | ||
| Q4 24 | $19.3M | $-47.7M | ||
| Q3 24 | — | $-91.7M | ||
| Q2 24 | $-8.4M | $-115.5M | ||
| Q1 24 | $-133.3M | $132.2M |
| Q4 25 | -7.1% | -1.0% | ||
| Q3 25 | 23.6% | -10.7% | ||
| Q2 25 | 2.5% | -19.2% | ||
| Q1 25 | -32.0% | 29.7% | ||
| Q4 24 | 9.1% | -12.2% | ||
| Q3 24 | — | -28.7% | ||
| Q2 24 | -4.2% | -43.1% | ||
| Q1 24 | -77.3% | 29.1% |
| Q4 25 | 0.1% | 2.8% | ||
| Q3 25 | 0.0% | 0.5% | ||
| Q2 25 | 0.0% | 1.4% | ||
| Q1 25 | 0.0% | 0.0% | ||
| Q4 24 | 0.0% | 0.9% | ||
| Q3 24 | 0.0% | 2.4% | ||
| Q2 24 | 0.0% | 1.8% | ||
| Q1 24 | 0.2% | 0.7% |
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -2.20× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
PLCE
| The Childrens Place US | $307.4M | 91% |
| The Childrens Place International | $32.1M | 9% |
| Gift Cards | $1.7M | 1% |
